Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series

Sergio Siragusa, Mariasanta Napolitano, Gaetano Giuffrida, Valeria Calafiore, Rita Carlotta Santoro, Fabio Gagliano, Filomena Daniele, Rita Carlotta Santoro, Maria Francesca Mansueto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


BAY 81-8973 is an unmodified, full-length third generation recombinant factor VIII (rFVIII) which offers a more favorable pharmacokinetic (PK) profile, compared to its predecessor sucrose-formulated rFVIII (rFVIII-FS). We here report on a retrospective case series of nine patients affected by hemophilia A (HA), with variable disease severity, bleeding phenotype and comorbidities, to underline our clinical practice on prophylaxis with a recently introduced standard hall-life recombinant Factor VIII. The current case series highlights how the current clinical management of hemophilia is able to personalize treatment in several specific conditions like concomitant illnesses with thrombotic risk and allergic reactions.
Original languageEnglish
Pages (from-to)102897-
Number of pages6
JournalTransfusion and Apheresis Science
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series'. Together they form a unique fingerprint.

Cite this